Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
试验速览
- 阶段
- 不适用
- 入组人数
- 1,130
- 试验地点
- 1
- 主要终点
- description of BJI/PJI
研究概览
简要总结
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
详细描述
Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013.
Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed
排除标准
- •Patients who objected to participating in the study
- •Absence of blood dosage of daptomycin
结局指标
主要结局
description of BJI/PJI
时间窗: between 2010 and 2020
type of BJI or PJI
description of adverse event
时间窗: between 2010 and 2020
type of adverse event
description of patients
时间窗: between 2010 and 2020
comorbidites
rate of patients having had a PJI or BJI treated by daptomycin
时间窗: between 2010 and 2020
proportion of patients treated by daptomycin
rate of patients having had an adverse event
时间窗: between 2010 and 2020
proportion of patients having had an adverse event under daptomycin
Evalutation of the adverse event due to daptomycin : duration of daptomycine
时间窗: between 2010 and 2020
description of the use of daptomycine : duration
Evalutation of the adverse event due to daptomycin : daptomycine plasma clearance
时间窗: between 2010 and 2020
mean daptomycine plasma clearance (unit, liters per hour)
Evalutation of the adverse event due to daptomycin : daptomycine volume distribution
时间窗: between 2010 and 2020
mean daptomycine volume of distribution (unit, liters)
Evalutation of the adverse event due to daptomycin : dosage of daptomycine
时间窗: between 2010 and 2020
description of the use of daptomycine : dosage
次要结局
未报告次要终点